The FDA granted orphan-drug status to Telik's Telintra, or ezatiostat HCL, an experimental drug for myelodysplastic syndrome. In studies, Telintra was associated with multilineage response and the need for fewer red blood cell transfusions among MDS patients.
Telik's MDS candidate Telintra wins orphan-drug designation
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan